PubMed Health⌕ Search

Biomedical subjects

M Marneur

Publications and source records attributed to M Marneur.

8 recordsLinked to original sources
PubMed1985

[Vindesine in oral cancers].

Vindesine, a vinblastine derivative, was evaluated in 36 patients with malignant tumours of the buccal cavity previously untreated. Vindesine was used (1) pre-operatively, in short, weekly intravenous courses for 1 to 3 weeks and (2) prior to radiotherapy of inoperable tumours, in prolonged treatments, either by bolus i.v. injections with vein washing weekly or, in case of failure, by continuous i.v. infusion over 5 days. In the first group major responses were obtained in 22.2% of the cases. In the second group only 1 of 18 patients responded to weekly injections, whereas 3 out of 10 patients responded to continuous infusion (including one complete remission), showing that this mode of administration was more effective than bolus injections. Toxic reactions to the drug are discussed. Venous damage was the predominant complication of continuous infusion.

Antineoplastic Agents↗
PubMed1983

[Bifractionated radiotherapy and oropharyngeal carcinoma].

The relatively poor results of therapy for epidermoid oropharyngeal carcinoma stages T3 and T4 suggested the need for new treatment regimens. A study involving 24 patients included bifractionated radiation on a daily basis, as used by J. C. Horiot and A. Nabib and then by the E.O.R.T.C. group. The more encouraging results reported by A. Nabib were not obtained. The 5-year survival rate will possibly be no better than after conventional external radiation. Post-radiotherapy complications were observed.

Aged↗
PubMed1980

[New drugs, new therapeutic regimens, and new strategies for chemotherapy of stomatological cancers (author's transl)].

Two new drugs have been proved to be effective for isolated or recurrent stomatological tumors : detorubicine (limited because of cardiotoxicity), and CDDP (limited because of renal and neurological toxicity). Drugs used mainly as adjuvant treatment concurrently with BCG, as immunotherapy, are bestatine (without clinical or biological toxicity) and levamisole (rare cases of agranulocytosis). Randomized trials of chemo- and immunotherapy now underway are the only means of assessing long-term efficacy of adjuvant treatments.

Adjuvants, Immunologic↗
PubMed1980

[Maxillary cancer. A retrospective study of 239 cases (author's transl)].

A study of the distribution of these cancers demonstrated that they were mainly epidermoid carcinomas (144 cases), cylindromas (38 cases), and sarcomas. The series included 58% of male patients, but the percentage of women is high because of the predominance of muco-epidermoid epitheliomas and hematosarcomas in female patients. Age distribution was identical for both sexes. The period between the first sign and the diagnosis varied according to the histological type (5 months for epidermoid carcinoma, 10 months for the cylindromas, and 28 months for muco-epidermoid epitheliomas). The initial examination revealed the presence of palpable glands in 40% of the cases with epidermoid cancer of the gums, as against 25% of those with facial epidermoid carcinomas. Survival rate after 5 years was 33% for epidermoid cancer, 72% for cylindromas, and 15% for muco-epidermoid epitheliomas. For epidermoid carcinomas, survival was related to their size (56% for T1, 52% for T2, 30% for T3, and 16% for T4). No significant differences in relation to the site of the lesion were found. The incidence of glandular invasion is of the greatest importance. All N3 cases died within 30 months. In fact, two categories of patients can be conveniently distinguished; those with T1, T2, T3, NO who have an overall mean survival rate of 68% after two years, and all the other cases with a mean survival rate of 28%.

Adult↗
PubMed1979

[Dental complications of irradiation : fluoride prophylaxis (author's transl)].

The authors review the studies describing dental changes after radiotherapy or curietherapy of the cervicofacial region published over the last 50 years. They discuss more particularly: --direct and indirect effects on the teeth,--lesions of the salivary glands,--dental lesions,--fluoride prophylaxis for dental lesions after irradiation.

Dentin↗
PubMed1979

[Dental problems before irradiation (author's transl)].

Before antitumoral facial irradiation, those teeth that cannot be conserved for a sufficiently long post-irradiation period of at least two years should be extracted. Teeth that are less affected, in patients given palliative treatment and in whom the prognosis is better, can be conserved. The conserved teeth are protected from destruction by the application of a fluoride gel. Dental reconstruction is ensured by the conventional methods, including the fixed prosthesis. The arches can be restored with atraumatic fixed prostheses but prudence is required. If extraction is necessary, a strict procedure must be employed and sufficient antibiotic treatment prescribed.

Dentures↗